The new 30,000m² facility, to be built on the grounds of the company’s existing bulk pharmaceutical manufacturing plant, will house six 15,000l bioreactors, purification area as well as
Around £4m has been set aside by GSK as initial funding round, which will support successful proposals from researchers in Côte d’Ivoire, Cameroon, Ghana, the Gambia, Nigeria, Kenya,
The company sNDA has been granted priority review status by the FDA and it was based on the results of a three-week monotherapy trial in 403 pediatric patients,
As per the auction process, Aurobindo emerged as best bidder with a bid of $132.5m to acquire the assets of Natrol with an agreement to take on certain
Symptoms of schizoaffective disorder are complex and without treatment they are disabling. Janssen Scientific Affairs director of Clinical Development Dong-Jing Fu said: "Schizoaffective disorder is a difficult-to-treat disease.
SSc is a rare multisystem, autoimmune disease that results in the overproduction and abnormal growth of collagen, which causes fibrosis of the skin and internal organs. dcSSc is
The company is focused on the development and commercialization of a once-daily, oral medication to treat liver diseases and cholesterol gallstones. The single center, randomized, double blind, placebo
The company said that the new delivery approaches seek to target the desired tissue more effectively. The deal builds on an existing collaboration between the two firms, and
The collaboration, which will leverage the strengths of both organizations, is aimed at accelerating the development of transformational new therapies for these underserved patients. The biobank at CHOP’s
ONL101 is a first-in-class small molecule peptide currently under development to protect photoreceptors in retinal detachment, a condition for which the product has been granted orphan disease designation.
Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.